FDAnews
www.fdanews.com/articles/176622-nice-greenlights-sanofi-amgen-cholesterol-lowering-drugs

NICE Greenlights Sanofi, Amgen Cholesterol-Lowering Drugs

May 12, 2016

The UK’s National Institute for Health and Care Excellence is backing cholesterol-lowering drugs from Sanofi and Amgen, provided the companies deliver discounted prices as promised.

In draft guidances released last week, the drug cost watchdog tentatively recommended that the National Health Service cover Sanofi’s Praluent and Amgen’s Repatha for adults with primary hypercholesterolemia or mixed dyslipidemia. NHS generally waits for a final recommendation before making its decision.

The injectable PCSK9 therapies — the newest class of cholesterol drugs — both proved to be significantly better at lowering LDL concentrations than the comparator drug ezetimibe, which costs only $550 per year but has shown limited benefits.

 

View More Stories